leadf
logo-loader
viewZelira Therapeutics Ltd

Zelira Therapeutics positions for future growth with transition to US-based leadership team led by Dr Oludare Odumosu

Dr Richard Hopkins has decided to step down as chief executive officer and managing director ex-USA effective May 15, 2021.

Zelira Therapeutics Ltd - Zelira Therapeutics positions itself for future growth with transition to US-based leadership team led by Dr Oludare Oludare Odumosu
Dr Hopkins will continue in his role while assisting and supporting the company through the transition period

Zelira Therapeutics Ltd’s (ASX:ZLD) (OTCQB:ZLDAF) (FRA:G1G) strategic consolidation of its operations will see leadership of the company transfer to the US-based team, with Dr Oludare Odumosu assuming the role of global managing director. 

Dr Richard Hopkins has decided to step down as chief executive officer and managing director ex-USA effective May 15, 2021. 

He will however continue in his role while assisting and supporting the company through the transition period. 

Strong achievements over past 12 months

Dr Hopkins said: “I have enjoyed establishing and leading the Australian-based Zelira team, whose achievements over the past 12 months, in particular, have been strong.

“These include helping facilitate the merger, delivering successful outcomes to two world-class clinical trials and launching three products into the Australian market.

“I’m looking forward to continuing to work with Dr Odumosu during the transition period.”

Position for future growth

Zelira chairman Osagie Imasogie said: “Richard has been instrumental in helping facilitate Zelira’s merger and transition to a global revenue-generating company.

“He has overseen the development of a pipeline of clinically validated products that recently launched on the Australian market and are now poised to enter global markets.

“With these outcomes successfully delivered, the time is right to position the company for future growth by transitioning to a US-based leadership team.

“This will allow Zelira to optimise its exposure to the rapidly expanding US cannabis sector while also continuing to grow its revenues in ex-USA markets.

“We thank Richard for all his efforts in taking Zelira’s ex-US operations forward during his tenure and wish him well in his future career.”

Quick facts: Zelira Therapeutics Ltd

Price: 0.064 AUD

ASX:ZLD
Market: ASX
Market Cap: $76.18 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Zelira Therapeutics Ltd named herein, including the promotion by the Company of Zelira Therapeutics Ltd in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Zelira Therapeutics sees 'multiple shots on goal' with a number of revenue...

Zelira Therapeutics Ltd’s (ASX:ZLD) (OTCQB:ZLDAF) (FRA:G1G) deputy chairman Harry Karelis speaks to Proactive's Andrew Scott soon after announcing a strategic consolidation of its operations which sees leadership of the company transfer to the US-based team, with Dr Oludare Odumosu assuming the...

1 week, 2 days ago

2 min read